TLANDO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tlando, and when can generic versions of Tlando launch?
Tlando is a drug marketed by Verity and is included in one NDA. There are fourteen patents protecting this drug.
This drug has thirty-seven patent family members in fifteen countries.
The generic ingredient in TLANDO is testosterone undecanoate. There are sixty-nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the testosterone undecanoate profile page.
DrugPatentWatch® Generic Entry Outlook for Tlando
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 8, 2029. This may change due to patent challenges or generic licensing.
There is one tentative approval for the generic drug (testosterone undecanoate), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
US Patents and Regulatory Information for TLANDO
TLANDO is protected by fifteen US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TLANDO is ⤷ Start Trial.
This potential generic entry date is based on patent 11,304,960.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
International Patents for TLANDO
When does loss-of-exclusivity occur for TLANDO?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 5538
Estimated Expiration: ⤷ Start Trial
Australia
Patent: 10203457
Estimated Expiration: ⤷ Start Trial
Patent: 14232475
Estimated Expiration: ⤷ Start Trial
Patent: 19200097
Estimated Expiration: ⤷ Start Trial
Brazil
Patent: 1007025
Estimated Expiration: ⤷ Start Trial
Patent: 2015020849
Estimated Expiration: ⤷ Start Trial
Canada
Patent: 44266
Estimated Expiration: ⤷ Start Trial
Patent: 42005
Estimated Expiration: ⤷ Start Trial
China
Patent: 2271665
Estimated Expiration: ⤷ Start Trial
Patent: 5073118
Estimated Expiration: ⤷ Start Trial
European Patent Office
Patent: 73295
Estimated Expiration: ⤷ Start Trial
Patent: 68363
Estimated Expiration: ⤷ Start Trial
Patent: 78368
Estimated Expiration: ⤷ Start Trial
Patent: 97762
Estimated Expiration: ⤷ Start Trial
Israel
Patent: 0958
Estimated Expiration: ⤷ Start Trial
Japan
Patent: 58812
Estimated Expiration: ⤷ Start Trial
Patent: 07711
Estimated Expiration: ⤷ Start Trial
Patent: 12514653
Estimated Expiration: ⤷ Start Trial
Patent: 15120700
Estimated Expiration: ⤷ Start Trial
Patent: 16514706
Estimated Expiration: ⤷ Start Trial
Mexico
Patent: 11007351
Estimated Expiration: ⤷ Start Trial
Patent: 15010594
Estimated Expiration: ⤷ Start Trial
Russian Federation
Patent: 22592
Estimated Expiration: ⤷ Start Trial
Patent: 15128028
Estimated Expiration: ⤷ Start Trial
South Africa
Patent: 1507700
Estimated Expiration: ⤷ Start Trial
South Korea
Patent: 2238478
Estimated Expiration: ⤷ Start Trial
Patent: 150129671
Estimated Expiration: ⤷ Start Trial
Taiwan
Patent: 1521731
Estimated Expiration: ⤷ Start Trial
Uruguay
Patent: 445
Estimated Expiration: ⤷ Start Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering TLANDO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2012075081 | ⤷ Start Trial | |
| World Intellectual Property Organization (WIPO) | 2018098501 | ⤷ Start Trial | |
| Russian Federation | 2722592 | ⤷ Start Trial | |
| Argentina | 095538 | ⤷ Start Trial | |
| Australia | 2010203457 | ⤷ Start Trial | |
| World Intellectual Property Organization (WIPO) | 2010081032 | ⤷ Start Trial | |
| South Korea | 102238478 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Investment Scenario, Market Dynamics, and Financial Trajectory for TLANDO
More… ↓
